FrancophonIA/ELRC3.0 huggingface dataset:
English: The preferred sites are anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in young children.
Croatian: Preporučena mjesta primjene su anterolateralni dio bedra u dojenčadi ili deltoidni mišić nadlaktice u male djece.
English: Any vaccine serotype IPD(3) - Invasive pneumonia or bacteraemia - Meningitis
Croatian: Bilo koji IPB serotip sadržan u cjepivu(3) - invazivna pneumonija ili bakterijemija - meningitis
English: The clinical relevance of these differences is not known.
Croatian: Klinički značaj ovih razlika nije poznat.
English: Read all of this leaflet carefully before your child receives this vaccine because it contains important information for you.
Croatian: Vaše dijete primi cjepivo jer sadrži Vama važne podatke.
English: This study has shown that the immune responses against the 7 common serotypes were comparable to those elicited by a booster dose of 7-valent Prevenar.
Croatian: Ovo ispitivanje je pokazalo da su imunološki odgovori na 7 zajedničkih serotipova bili usporedivi s onima dobivenima uz dozu docjepljivanja 7-valentnog cjepiva Prevenar.
English: Booster dose at 9-12 versus 15-18 months of age
Croatian: Docjepljivanje u dobi od 9 - 12 mjeseci naspram 15 - 18 mjeseci
English: Use with systemic immunosuppressive medicinal products
Croatian: Primjena sa sistemskim imunosupresivnim lijekovima
English: In clinical trials, Synflorix elicited an immune response to all ten serotypes included in the vaccine, but the magnitude of the responses varied between serotypes.
Croatian: U kliničkim ispitivanjima Synflorix je izazvao imunološki odgovor na svih deset serotipova sadržanih u cjepivu, ali jačina odgovora je varirala između serotipova.
English: In children as of 2 years of age, syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection.
Croatian: Kod djece od 2 godine može se dogoditi sinkopa (nesvjestica) nakon, ili čak i prije cijepljenja kao psihogena reakcija na ubod s iglom.
English: N number of subjects per group n/% number/percentage of subjects reporting a first episode of B-CAP anytime from 2 weeks after the administration of the 3rd dose
Croatian: N broj ispitanika po skupini n/% broj/postotak ispitanika koji su prijavili prvu epizodu B-CAP u bilo kojem trenutku nakon isteka
English: Booster doses of Synflorix may increase the risk of side effects.
Croatian: Doza docjepljivanja cjepiva Synflorix može povećati rizik od nuspojava.
English: Acute otitis media (AOM) is a common childhood disease with different aetiologies.
Croatian: Akutna upala srednjeg uha (engl. acute otitis media, AOM) je česta bolest u djetinjstvu, s različitim etiologijama.
English: In all trials, Synflorix was administered concurrently with the recommended childhood vaccines.
Croatian: U svim ispitivanjima Synflorix je primjenjivan istodobno s preporučenim dječjim cjepivima.
English: In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.
Croatian: Kod djece rođene znatno prije termina (s 28 ili prije 28 tjedana gestacije) 2 - 3 dana nakon cijepljenja mogu se pojaviti pauze u disanju dulje od normalnih.
English: In COMPAS, 7,214 subjects [Total Vaccinated cohort (TVC)] were included in the AOM efficacy analysis of which 5,989 subjects were in the ATP cohort (Table 3).
Croatian: U ispitivanju COMPAS je u analizu djelotvornosti protiv AOM-a bilo uključeno 7214 ispitanika (cjelokupna procijepljena kohorta), od kojih je 5989 ispitanika bilo u ATP kohorti (Tablica 3).
English: In individuals who have underlying conditions predisposing them to invasive pneumococcal disease (such as Human Immunodeficiency Virus (HIV) infection, sickle cell disease (SCD) or splenic dysfunction), Synflorix may be given according to the above mentioned schedules except that a 3-dose schedule should be given as primary vaccination in infants starting vaccination from 6 weeks to 6 months of age (see sections 4.4 and 5.1).
Croatian: U osoba koje imaju podležeća stanja koja predstavljaju predispoziciju za invazivnu pneumokoknu bolest (kao što su infekcija virusom humane imunodeficijencije [HIV], anemija srpastih stanica ili poremećaj funkcije slezene), Synflorix se može primijeniti u skladu s gore navedenim rasporedom osim što se raspored cijepljenja s 3 doze mora primjeniti kao primarna imunizacija u dojenčadi kod koje se započinje s cijepljenjem u dobi od 6 tjedana do 6 mjeseci (vidjeti dijelove 4.4 i 5.1).
English: Unvaccinated infants and children ≥ 7 months of age:
Croatian: Necijepljena dojenčad i djeca u dobi od ≥ 7 mjeseci:
English: Synflorix should under no circumstances be administered intravascularly or intradermally.
Croatian: Synflorix se ne smije niti u kojem slučaju primjenjivati intravaskularno ili intradermalno.
English: The OPA response for serotypes 1 and 5 was lower in magnitude than the response for each of the other serotypes.
Croatian: Veličina OPA odgovora za serotipove 1 i 5 bila je manja nego odgovor za svaki od ostalih serotipova.
English: In a head-to-head comparative trial with 7-valent Prevenar, non-inferiority of the immune response to Synflorix measured by ELISA was demonstrated for all serotypes, except for 6B and 23F (upper limit of the 96.5% CI around the difference between groups >10%) (Table 6).
Croatian: U izravnom (“head-to-head”) komparativnom ispitivanju sa 7-valentnim cjepivom Prevenar pokazana je neinferiornost imunološkog odgovora na Synflorix, mjereno pomoću ELISA, za sve serotipove, osim za 6B i 23F (gornja granica 96,5% CI oko razlike između skupina > 10%) (Tablica 6).
English: After NIP
Croatian: Nakon NPI-a
English: No increase in the incidence or severity of the adverse reactions was seen with subsequent doses of the primary vaccination series.
Croatian: Nije primijećeno povećanje incidencije ili težine nuspojava s primjenom sljedećih doza u primarnom cijepljenju.
English: • In children aged 12-23 months, the immune responses elicited after two doses were comparable to the responses elicited after three doses in infants below 6 months of age, except for vaccine serotypes 18C and 19F as well as serotype 19A for which responses were higher in the 12-23 months children.
Croatian: • U djece u dobi od 12 do 23 mjeseca, imunološki odgovori postignuti nakon dvije doze bili su usporedivi s odgovorima nastalima nakon tri doze u dojenčadi mlađe od 6 mjeseci, osim za serotipove 18C i 19F sadržane u cjepivu kao i za serotip 19A za koje su odgovori bili veći u djece u dobi od 12 do 23 mjeseca.
English: In the event of either being observed, discard the vaccine.
Croatian: U slučaju da primijetite nešto od spomenutog, odbacite cjepivo.
English: Vaccine efficacy n
Croatian: Djelotvornost cjepiva n
English: schedule schedule
Croatian: raspored raspored
English: Immunogenicity and safety of Synflorix were assessed in a limited number of primed or unprimed subjects with congenital or acquired asplenia, splenic dysfunction or complement deficiencies: 6 subjects 2-5 years of age and 40 subjects 6-17 years of age (Synflorix is indicated up to 5 years of age).
Croatian: Imunogenost i sigurnost primjene cjepiva Synflorix procijenjeni su u ograničenom broju ispitanika koji su primili primarno cijepljenje ili ispitanika koji nisu primili primarno cijepljenje s kongenitalnom ili stečenom asplenijom, poremećajima funkcije slezene ili nedostatcima komplementa: 6 ispitanika u dobi od 2 do 5 godina i 40 ispitanika u dobi od 6 do 17 godina (Synflorix je indiciran do 5 godina starosti).
English: There are no data available to indicate whether the administration of pneumococcal polysaccharide vaccine to Synflorix primed children may result in hyporesponsiveness to further doses of pneumococcal polysaccharide or to pneumococcal conjugate vaccine.
Croatian: Nema dostupnih podataka koji ukazuju može li primjena pneumokoknog polisaharidnog cjepiva u djece koja su primarno primila Synflorix rezultirati smanjenom osjetljivošću na daljnje doze pneumokoknog polisaharidnog ili na pneumokokno konjugirano cjepivo.
English: Synflorix is a pneumococcal conjugate vaccine.
Croatian: Synflorix je konjugirano cjepivo protiv pneumokoka.
English: Immune responses were compared using non-inferiority criteria in terms of antibody GMC ratio (GMC from group of subjects receiving Synflorix without 2-PE over GMC from group of subjects receiving Synflorix with 2-PE) for each of the 10 vaccine serotypes and for the cross-reactive serotype 19A.
Croatian: Imunološki odgovori su uspoređeni korištenjem kriterija ne-inferiornosti u smislu omjera GMC protutijela (GMC iz skupine ispitanika koji su primali Synflorix bez 2-PE prema GMC-u iz skupine ispitanika koji su primali Synflorix s 2-PE) za svaki od 10 serotipova cjepiva i za križno reaktivni serotip 19A.
English: Although there was no significant difference between the two groups in the percentages of subjects with antibody concentration ≥ 0.20 µg/ml (ELISA), the percentages of subjects for serotypes 6B and 23F were lower than for the other vaccine serotypes (Table 7 and Table 8).
Croatian: Iako nije bilo statistički značajne razlike između dviju skupina u postotku cijepljenih s koncentracijom protutijela ≥ 0,20 µg/ml (ELISA), postotak ispitanika za serotipove 6B i 23F je bio niži nego za ostale serotipove sadržane u cjepivu (Tablica 7 i Tablica 8).
English: As for other vaccines administered intramuscularly, Synflorix should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.
Croatian: Poput ostalih cjepiva koja se primjenjuju intramuskularno, Synflorix se mora davati s oprezom u djece s trombocitopenijom ili poremećajem koagulacije, s obzirom da u njih može doći do krvarenja nakon intramuskularne primjene.
English: In a clinical study, it has been demonstrated that Synflorix can be safely administered as a booster dose in the second year of life to children who had received 3 primary doses of 7-valent Prevenar.
Croatian: U kliničkom ispitivanju je pokazano da se Synflorix može sigurno primijeniti kao doza docjepljivanja u drugoj godini života u djece koja su primila 3 doze primarne imunizacije 7-valentnim cjepivom Prevenar.
English: Each injection will be given at least one month apart.
Croatian: Svaka injekcija se daje u razmaku od najmanje jednog mjeseca.
English: When using a multidose vial, each 0.5 ml dose should be withdrawn using a sterile needle and syringe; precautions should be taken to avoid contamination of the contents.
Croatian: Kod primjene višedozne bočice, svaka 0,5 ml doza mora se navući sterilnom iglom i injekcijom, potreban je oprez kako bi se izbjegla kontaminacija sadržaja.
English: Vaccine effectiveness or efficacy (VE) was demonstrated in preventing culture-confirmed IPD due to vaccine pneumococcal serotypes when Synflorix was given to infants in either 2+1 or 3+1 schedules in FinIP or 3+1 schedule in COMPAS (see Table 1).
Croatian: Učinkovitost ili djelotvornost cjepiva (UC/DC) pokazana je u prevenciji IPB-a potvrđenog kulturom, a uzrokovanog serotipovima pneumokoka zastupljenima u cjepivu kada je Synflorix dan dojenčadi u rasporedu 2+1 ili 3+1 u ispitivanju FinIP ili u rasporedu 3+1 u ispitivanju COMPAS (vidjeti Tablicu 1).
English: Unvaccinated infants and children ≥ 7 months of age
Croatian: Necijepljena dojenčad i djeca u dobi od ≥ 7 mjeseci
English: The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.
Croatian: Mora se razmotriti potencijalan rizik od apneje i potreba za praćenjem funkcije disanja tijekom 48 - 72 sata kod primarne imunizacije prijevremeno rođene dojenčadi (rođene prije ili s 28 tjedana gestacije), a osobito one s anamnezom nezrelosti dišnog sustava.
English: Immunogenicity of Synflorix containing the preservative 2-PE (presented in a 4-dose container) was assessed in healthy infants vaccinated at 6, 10 and 18 weeks of age and compared to those receiving Synflorix without added preservative (160 enrolled subjects per group).
Croatian: Imunogenost cjepiva Synflorix koji sadrži konzervans 2-fenoksietanol (2-PE) (nalazi se u 4-doznom spremniku) je ocjenjena u zdrave dojenčadi koja su cjepljena u dobi od 6, 10 i 18 tjedana i uspoređena s onom koja su primila cjepivo Synflorix bez dodanog konzervansa (160 uključenih ispitanika po skupini).
English: 5-10 micrograms
Croatian: 5 - 10 mikrograma
English: The OPA GMTs were similar or higher following a single dose than a 3-dose primary course in infants below 6 months of age, except for serotype 5.
Croatian: OPA GMT-i su bili podjednaki ili viši nakon jedne doze nego nakon primarnog ciklusa cijepljenja dojenčadi mlađe od 6 mjeseci s tri doze, osim za serotip 5.
English: Immunogenicity of Synflorix containing the preservative 2-phenoxyethanol (2-PE)
Croatian: Imunogenost cjepiva Synflorix koji sadrži konzervans 2-fenoksietanol (2-PE)
English: Immunogenicity data in preterm infants
Croatian: Podaci o imunogenosti u prijevremeno rođene dojenčadi
English: Allergic reactions (such as eczema, allergic dermatitis, atopic dermatitis)
Croatian: Poremećaji imunološkog sustava rijetko alergijske reakcije (kao što su ekcem, alergijski dermatitis, atopijski dermatitis) vrlo rijetko angioedem
English: These can be recognised by: - raised and itchy rash (hives) - swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing - collapse
Croatian: - izdignutom osipu praćenom svrbežom (koprivnjača) - oticanju koje ponekad zahvaća lice i usta (angioedem) i koje uzrokuje poteškoće s disanjem
English: In subjects that had received a 3-dose primary series followed by a booster dose, at least 96.5% of the subjects remained seropositive for vaccine serotypes and 86.4% for serotype 19A.
Croatian: U ispitanika koji su primarno cijepljeni s 3 doze i potom primili dozu docjepljivanja, najmanje 96,5% ispitanika je ostalo seropozitivno na serotipove sadržane u cjepivu i 86,4% na serotip 19A.
English: Each 0.5 ml dose contains 1 microgram of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14 and 23F, and 3 micrograms for serotypes 4, 18C and 19F
Croatian: Jedna doza od 0,5 ml sadrži 1 mikrogram polisaharida serotipova 1, 5, 6B, 7F, 9V, 14 i 23F, i 3 mikrograma serotipova 4, 18C i 19F.
English: A clinical study conducted in India assessing a booster dose given at 9-12 or 15-18 months of age in 66 and 71 children, respectively, following primary vaccination at 6, 10 and 14 weeks of age, did not suggest differences between groups in terms of antibody GMCs.
Croatian: Kliničko ispitivanje provedeno u Indiji, u kojem se ocjenjivala doza docjepljivanja primijenjena u dobi od 9 - 12 mjeseci kod 66 djece odnosno u dobi od 15 - 18 mjeseci kod 71 djeteta, nakon primarnog cijepljenja u dobi od 6-10-14 tjedana, nije ukazalo na razlike između skupina s obzirom na GMC-e protutijela.
English: Each injection will be given at least two months apart.
Croatian: Svaka injekcija se daje u razmaku od najmanje dva mjeseca.
English: Synflorix should not be mixed with other vaccines.
Croatian: Synflorix se ne smije miješati s drugim cjepivima.
English: In another large randomised double-blind trial (POET) conducted in the Czech Republic and in Slovakia, 4,907 infants (ATP cohort) received either the 11-valent investigational vaccine (11Pn-PD) containing the 10 serotypes of Synflorix (along with serotype 3 for which efficacy was not demonstrated) or a control vaccine (hepatitis A vaccine) according to a 3, 4, 5 and 12-15 months vaccination schedule.
Croatian: U drugom velikom randomiziranom, dvostruko-slijepom ispitivanju (POET) provedenom u Republici Češkoj i Slovačkoj, 4907 dojenčadi (ATP kohorta) primilo je ili ispitivano 11-valentno cjepivo (11PnPD) koje sadrži 10 serotipova cjepiva Synflorix (zajedno sa serotipom 3 za koji djelotvornost nije pokazana) ili kontrolno cjepivo (cjepivo protiv hepatitisa A) prema 3, 4, 5 i 12-15-mjesečnom rasporedu cijepljenja.
English: No data are available on subcutaneous administration of Synflorix.
Croatian: Nisu dostupni podaci o supkutanoj primjeni cjepiva Synflorix.
English: Children with a weakened immune system (such as due to human immunodeficiency virus (HIV) infection or immunosuppressive therapy) may not get the full benefit from Synflorix.
Croatian: Djeca s oslabljenim imunološkim sustavom (zbog npr. infekcije virusom humane imunodeficijencije (HIV) ili terapije koja potiskuje imunološki sustav) ne moraju postići potpuni pozitivan učinak cjepiva Synflorix.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF PRE-FILLED SYRINGE WITH OR WITHOUT NEEDLE, PACK OF 1, 10, 50
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA NAPUNJENE ŠTRCALJKE S ILI BEZ IGLE, PAKIRANJE OD 1, 10, 50
English: In the same study, Synflorix was shown to elicit functional antibodies to all vaccine serotypes.
Croatian: U istom ispitivanju, pokazalo se da nakon cijepljenja cjepivom Synflorix nastaju funkcionalna protutijela protiv svih serotipova iz cjepiva.
English: Table 2: Numbers and percentages of subjects with first episodes of B-CAP occurring from 2 weeks after the administration of the 3rd dose of Synflorix or control vaccine and vaccine efficacy (ATP cohort)
Croatian: Tablica 2: Brojevi i postotci ispitanika u kojih su se prve epizode B-CAP počele javljati 2 tjedna nakon primjene 3. doze cjepiva Synflorix ili kontrolnog cjepiva te djelotvornost cjepiva (ATP kohorta)
English: 3 conjugated to tetanus toxoid carrier protein
Croatian: 3 konjugiran na tetanusni toksoid proteinski nosač
English: In addition when the meningococcal serogroups A, C, W-135 and Y vaccine (TT conjugate) was coadministered with a booster dose of Synflorix during the second year of life in children primed with 3 doses of Synflorix, lower antibody geometric mean concentration (GMC) and opsonophagocytic assay geometric mean titre (OPA GMT) were observed for one pneumococcal serotype (18 C).
Croatian: Nadalje, kada se cjepivo protiv meningokoka serogrupa A, C, W-135 i Y (TT konjugat) primjenjivalo istodobno s dozom docjepljivanja cjepiva Synflorix tijekom druge godine života u djece koja su primila 3 primarne doze cjepiva Synflorix, za jedan je pneumokokni serotip (18 C) primijećena niža geometrijska srednja koncentracija (engl. geometric mean concentration, GMC) protutijela i niži geometrijski srednji titar u opsonofagocitnom testu (OPA GMT).
English: Clinical data suggest that prophylactic administration of paracetamol, used to reduce the rate of possible post-vaccination febrile reactions, might reduce the immune response to Synflorix.
Croatian: Klinički podaci ukazuju na to da bi profilaktička primjena paracetamola, koji se koristi za sniženje stope mogućih febrilnih reakcija nakon cijepljenja, mogla smanjiti imunološki odgovor na Synflorix.
English: Vaccine efficacy results in children > 36 months of age suggest a waning of protection.
Croatian: > 36 mjeseci ukazuju na slabljenje zaštite.
English: The functional immune response to serotypes 1 and 5 was lower in magnitude than the response against all other vaccine serotypes.
Croatian: Funkcionalni imunološki odgovor na serotipove 1 i 5 bio je slabiji u odnosu na odgovor na sve druge serotipove sadržane u cjepivu.
English: In Quebec, Canada, Synflorix was introduced into the infant immunisation programme (2 primary doses to infants less than 6 months of age and a booster dose at 12 months) following 4.5 years of use of 7-valent Prevenar.
Croatian: U Quebecu, Kanada, Synflorix je uveden u program imunizacije dojenčadi (2 doze primarne imunizacije za dojenčad mlađu od 6 mjeseci i doza docjepljivanja u 12 mjesecu) nakon 4,5 godine korištenja 7-valentnog cjepiva Prevenar.
English: The immune responses after the booster dose in this age group were generally similar to those observed after the booster dose in infants who had been primed with 3 doses below 6 months of age.
Croatian: Imunološki odgovor nakon doze docjepljivanja u ovoj dobnoj skupini bio je općenito sličan onom primijećenom nakon doze docjepljivanja u dojenčadi mlađe od 6 mjeseci koja su primila 3 primarne doze cjepiva.
English: The use of prophylactic antipyretic medicinal products is recommended: - for all children receiving Synflorix simultaneously with vaccines containing whole cell pertussis because of higher rate of febrile reactions (see section 4.8).
Croatian: Preporučuje se profilaktička primjena antipiretičkog lijeka: - za svu djecu koja primaju Synflorix istovremeno s cjepivima koja sadrže cjelostanično cjepivo protiv pertusisa zbog više stope febrilnih reakcija (vidjeti dio 4.8). - za djecu s konvulzivnim napadajima ili s prethodnom anamnezom febrilnih konvulzija.
English: These results are indicative of immunological memory in primed subjects for all vaccine serotypes and the cross-reactive serotype 19A.
Croatian: Ovi rezultati ukazuju na imunološku memoriju u primarno cijepljenih ispitanika za sve serotipove sadržane u cjepivu i ukriženo reaktivni serotip 19A.
English: This bacteria can cause serious illnesses including meningitis, sepsis and bacteraemia (bacteria in blood stream) as well as ear infection or pneumonia.
Croatian: Ova bakterija može izazvati ozbiljne bolesti, uključujući upalu moždanih ovojnica, sepsu i bakterijemiju (bakterije u krvotoku), kao i infekciju uha ili upalu pluća.
English: The difference between both vaccines in terms of percentage of subjects with OPA titres ≥ 8 was <5% for all serotypes in common, including 6B and 23F.
Croatian: Razlika između oba cjepiva u postotku cijepljenih s OPA titrima ≥ 8 bila je manja od 5% za sve zajedničke serotipove, uključujući 6B i 23F.
English: Additional immunogenicity data
Croatian: Dodatni podaci o imunogenosti
English: Following booster vaccination, the most common adverse reactions were pain at the injection site and irritability, which occurred at approximately 51% and 53% respectively.
Croatian: Nakon docjepljivanja najčešće nuspojave bile su bol na mjestu injekcije i razdražljivost, a javile su se u približno 51% odnosno 53% slučajeva.
English: Booster dose at 9-10 months of age
Croatian: Docjepljivanje u dobi od 9 - 10 mjeseci
English: Safety and immunogenicity data are available for HIV infected infants (asymptomatic or with mild symptoms according to WHO classification), HIV negative infants born from HIV positive mothers, children with sickle cell disease and children with splenic dysfunction (see sections 4.8 and 5.1).
Croatian: Dostupni su podaci o sigurnosti primjene i imunogenosti u dojenčadi s HIV-infekcijom (asimptomatskom ili blago simptomatskom prema klasifikaciji SZO-a), HIV-negativne dojenčadi koju su rodile HIV-pozitivne majke, djece s anemijom srpastih stanica i djece s poremećajima funkcije slezene (vidjeti dijelove 4.8 i 5.1).
English: N=10,295
Croatian: Synflorix N=10 295
English: Two efficacy studies, COMPAS and POET (Pneumococcal Otitis Media Efficacy Trial), were conducted with pneumococcal conjugate vaccines containing protein D: Synflorix and an investigational 11-valent conjugate vaccine (which in addition contained serotype 3), respectively.
Croatian: Provedena su dva ispitivanja djelotvornosti - COMPAS i POET (Pneumococcal Otitis Media Efficacy Trial - ispitivanje djelotvornosti protiv pneumokoknog otitisa media) - u kojima su se primjenjivala konjugirana pneumokokna cjepiva koja sadrže protein D: Synflorix odnosno ispitivano 11-valentno konjugirano cjepivo (koje je dodatno sadržavalo i serotip 3).
English: • pain, redness and swelling where the injection is given
Croatian: • bol, crvenilo i oteklina na mjestu davanja injekcije
English: It is recommended that subjects who receive a first dose of Synflorix complete the full vaccination course with Synflorix.
Croatian: Preporučuje se da djeca cijepljena prvom dozom cjepiva Synflorix u potpunosti završe ciklus cijepljenja cjepivom Synflorix.
English: Prophylactic use of antipyretics
Croatian: Profilaktička primjena antipiretika